ViroCell released in the UK to make viral vectors

ViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.

ViroCell Launched in the UK to Manufacture Viral Vectors

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, PharmTech.com, gene therapy, cell therapy, AAV vectors, lentivirus vectors, UK CDMO, Farzin Farzaneh, Truell Conservation Foundation, Edmund Truell, King's College London, vector design, CGT

First UK-based clinical trial focused viral vector manufacturer announces launch...

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, PharmaTimes, vector design, AAV vectors, lentivirus vectors, UK CDMO, CGT, gene therapy, cell therapy, Truell Conservation Foundation

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the primary clinical trial focused viral vector manufacturer within the UK, has introduced its official launch, with the intention of turning into the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, ViroCell, Farzin Farzaneh, Truell Conservation Foundation, John Hadden II, gene therapy, cell therapy, CGT, UK CDMO, UR ALL news, vector design, AAV vectors, lentivirus vectors

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 28, 2021CDMO, ViroCell, Truell Conservation Foundation, Farzin Farzaneh, John Hadden II, gene therapy, cell therapy, CGT, viral vector, viral vectors, vector design, AAV vectors, lentivirus vectors, UK CDMO, PharmaJobs

In the news

London New York